ArticleExperimental eye research2009
sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised.
Article in Experimental eye research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Lipidomics in Periodontal Disease Research: A Systematic Review.Current medicinal chemistry · 2025Pooled it
- Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures.Investigative ophthalmology & visual science · 2013Trial
- Differential Tear Lipid Metabolomics Signatures Discriminate Superior Limbic Keratoconjunctivitis From Dry Eye Disease.Translational vision science & technology · 2025Article
- Synthesis, molecular modelling, and biological evaluation of novel quinoxaline derivatives for treating type II diabetes.Journal of enzyme inhibition and medicinal chemistry · 2024Article
- Chronic Tear Deficiency Sensitizes Transient Receptor Potential Vanilloid 1-Mediated Responses in Corneal Sensory Nerves.Frontiers in cellular neuroscience · 2020Article
- High sPLA2-IIA level is associated with eicosanoid metabolism in patients with bacterial sepsis syndrome.PloS one · 2020Article
- The Role of SKQ1 (Visomitin) in Inflammation and Wound Healing of the Ocular Surface.Ophthalmology and therapy · 2019Article
- Proteomic analysis of human lacrimal and tear fluid in dry eye disease.Scientific reports · 2017Article
- TFOS DEWS II Tear Film Report.The ocular surface · 2017Review
- The Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical Research.Investigative ophthalmology & visual science · 2017Review
- ω-3 Tear Film Lipids Correlate With Clinical Measures of Dry Eye.Investigative ophthalmology & visual science · 2016Article
- The core mechanism of dry eye disease is inflammation.Eye & contact lens · 2014Review
- Oleanolic acid controls allergic and inflammatory responses in experimental allergic conjunctivitis.PloS one · 2014Article
- Dry eye disease and microbial keratitis: is there a connection?The ocular surface · 2013Review
- Surfactant protein D contributes to ocular defense against Pseudomonas aeruginosa in a murine model of dry eye disease.PloS one · 2013Article
- Change in prostaglandin expression levels and synthesizing activities in dry eye disease.Ophthalmology · 2012Article
- Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model.Molecular vision · 2012Article
- Comparison of mucin levels at the ocular surface of postmenopausal women with and without a history of dry eye.Cornea · 2011Article
- sPLA2-IIa amplifies ocular surface inflammation in the experimental dry eye (DE) BALB/c mouse model.Investigative ophthalmology & visual science · 2011Article
- Quantification of tear proteins and sPLA2-IIa alteration in patients with allergic conjunctivitis.Molecular vision · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
sPLA2-IIa is an enzyme at high concentration in tears that has been known as an innate barrier of the ocular surface against microbial infection. sPLA2-IIa and other enzymes in the same protein family are known to hydrolyze fatty acids resulting in the generation of free arachidonic acid (AA) and lysophospholipids, which are the precursors of pro-inflammatory lipid mediators, such as PGE(2). sPLA2-IIa has been shown to be an inflammatory mediator in non-ocular inflammatory diseases such as rheumatoid arthritis (RA). It was also found to be increased in the tears of the patients with dry eye disease, chronic blepharitis and contact lens intolerance. However, the role of sPLA2-IIa in chronic ocular surface inflammation has yet to be determined. In the current study, we examined the potential role of sPLA2-IIa in inflammation of ocular surface diseases. Our results show that the activity of sPLA2-IIa was significantly increased in tears from dry eye disease patients compared with that from normal subjects. Also, sPLA2-IIa stimulated the production of PGE(2) in ocular surface epithelial cell cultures. The stimulating effect was markedly enhanced when the cells or tissues were pre-compromised with TNF-alpha, IL-1beta or desiccation. Furthermore, sPLA2-IIa stimulated inflammatory cytokine production in the ocular surface epithelial cell cultures in vitro. To our knowledge, this is the first report regarding the role of sPLA2-IIa as an inflammatory mediator in ocular surface inflammation. These findings indicate that sPLA2-IIa may play an important role in chronic ocular surface inflammation, especially when the ocular surface is compromised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.